Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Molecular And Nutritional Markers In Head And Neck Cancer.

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Molecular And Nutritional Markers In Head And Neck Cancer.

Related Experiment Video

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Molecular and nutritional markers in head and neck cancer.

Gerard Milano¹, Jocelyn Gal², René-Jean Bensadoun³

¹University Côte d'Azur, Centre Antoine Lacassagne, Scientific Valorisation Department.

Current Opinion in Oncology

|March 5, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Biomarkers for squamous cell carcinoma of the head and neck (SCCHN) are needed. Liquid biopsies, including circulating tumor cells (CTCs), show promise for predicting patient outcomes in SCCHN management.

More Related Videos

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

Related Experiment Videos

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

Area of Science:

Oncology
Biomarker Research
Head and Neck Cancer

Background:

Squamous cell carcinoma of the head and neck (SCCHN) management requires reliable predictive and prognostic biomarkers, particularly in induction and neoadjuvant settings.
Current biomarkers like p16 (human papilloma virus [HPV] positivity) indicate favorable prognosis but show variability in disease progression.
The correlation between immunohistochemistry (IHC) for epidermal growth factor receptors (EGFRs) and response to targeted therapies remains unclear due to quantification issues.

Approach:

This review synthesizes current knowledge on predictive and prognostic biomarkers for SCCHN.
It examines the utility of established markers and emerging technologies like circulating tumor cells (CTCs).
The focus is on biomarkers relevant to clinical decision-making in SCCHN treatment.

Key Points:

HPV positivity, indicated by p16, is associated with a better prognosis in SCCHN, though outcomes can vary.
EGFR expression measured by IHC does not consistently predict response to EGFR-targeted therapies.
Circulating tumor cells (CTCs) may offer insights into primary tumor mutations and have potential for outcome prediction via single-cell analysis.

Conclusions:

No definitive biological marker for clinical use in SCCHN outcome prediction has emerged yet.
Liquid biopsies, specifically circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), represent a promising future direction.
Further research into liquid biopsy applications could significantly advance SCCHN patient management.